Petro Halkowycz

Takeda (United States) — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

9h-index361citations26works1.72yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Microtubule and mitosis dynamics(10), Cancer-related Molecular Pathways(7), Cancer, Hypoxia, and Metabolism(6), Melanoma and MAPK Pathways(5), Synthesis and biological activity(4)

Publications26 total

POS0015 Zasocitinib (TAK-279) exhibits high levels of TYK2 inhibition and no inhibition of JAK 1/3 when compared with licensed TYK2 and JAK inhibitors
Annals of the Rheumatic Diseases·2025Open Access
Pharmacological Characterization of Zasocitinib (TAK-279): An Oral, Highly Selective, and Potent Allosteric TYK2 Inhibitor
Journal of Investigative Dermatology·2025· 4 citedOpen Access
De novo discovery of cyclic peptide inhibitors of IL-11 signaling
Bioorganic & Medicinal Chemistry·2024· 1 citedOpen Access
Supplementary Figure Legends from Biological Characterization of TAK-901, an Investigational, Novel, Multitargeted Aurora B Kinase Inhibitor
2023Open Access
Data from Biological Characterization of TAK-901, an Investigational, Novel, Multitargeted Aurora B Kinase Inhibitor
2023Open Access
Data from Biological Characterization of TAK-901, an Investigational, Novel, Multitargeted Aurora B Kinase Inhibitor
2023Open Access
Supplementary Figure 1 from Biological Characterization of TAK-901, an Investigational, Novel, Multitargeted Aurora B Kinase Inhibitor
2023Open Access
Supplementary Figure 2 from Biological Characterization of TAK-901, an Investigational, Novel, Multitargeted Aurora B Kinase Inhibitor
2023Open Access
Supplementary Figure 1 from Biological Characterization of TAK-901, an Investigational, Novel, Multitargeted Aurora B Kinase Inhibitor
2023Open Access
Supplementary Figure Legends from Biological Characterization of TAK-901, an Investigational, Novel, Multitargeted Aurora B Kinase Inhibitor
2023Open Access
Supplementary Figure 2 from Biological Characterization of TAK-901, an Investigational, Novel, Multitargeted Aurora B Kinase Inhibitor
2023Open Access
Correction to “Discovery of the Bruton’s Tyrosine Kinase Inhibitor Clinical Candidate TAK-020 (<i>S</i>)-5-(1-((1-Acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-2,4-dihydro-3<i>H</i>-1,2,4-triazol-3-one, by Fragment-Based Drug Design”
Journal of Medicinal Chemistry·2021· 3 citedOpen Access
Biochemical and Cellular Profile of NIK Inhibitors with Long Residence Times
SLAS DISCOVERY·2020· 1 citedOpen Access
Structure-guided optimization of a novel class of ASK1 inhibitors with increased sp3 character and an exquisite selectivity profile
Bioorganic & Medicinal Chemistry Letters·2020· 12 citedOpen Access
Rational discovery of a highly novel and selective mTOR inhibitor
Bioorganic & Medicinal Chemistry Letters·2019· 3 citedOpen Access
Correction to “Structure-Based Design of ASK1 Inhibitors as Potential Agents for Heart Failure”
ACS Medicinal Chemistry Letters·2017· 2 citedOpen Access
Discovery of potent and orally active 1,4-disubstituted indazoles as novel allosteric glucokinase activators
Bioorganic & Medicinal Chemistry Letters·2017· 19 citedOpen Access
Structure-based drug design of novel ASK1 inhibitors using an integrated lead optimization strategy
Bioorganic & Medicinal Chemistry Letters·2017· 19 citedOpen Access
Structure-Based Design of ASK1 Inhibitors as Potential Agents for Heart Failure
ACS Medicinal Chemistry Letters·2017· 43 citedOpen Access
Structure-based optimization of 1H-imidazole-2-carboxamides as Axl kinase inhibitors utilizing a Mer mutant surrogate
Bioorganic & Medicinal Chemistry Letters·2016· 12 citedOpen Access
page 1 of 2Next →

Frequent Co-authors

Ron de Jong(13), Deepika Balakrishna(12), Charles E. Grimshaw(12), Pamela Farrell(11), Lilly Zhang(11), Jennifer Matuszkiewicz(10), Robyn Fabrey(10), Bumsup Lee(10), Bi‐Ching Sang(10), Bheema Paraselli(10), Seigo Ishino(9), Toshiyuki Nomura(9), Mika Teratani(9), Yoshikazu Ohta(9), Lihong Shi(8), Takashi Hoshino(8), Sarah Elliott(8), Takashi Satou(8), Douglas R. Dougan(7), Lihong Shi(6)